J Pediatr Intensive Care 2019; 08(02): 071-077
DOI: 10.1055/s-0038-1667380
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Practice Patterns after the Therapeutic Hypothermia After Pediatric Cardiac Arrest Out-of-Hospital Trial: A Survey of Pediatric Critical Care Physicians

Authors

  • Marianne R. Gildea

    1   Department of Pediatrics, University of Utah, Salt Lake City, Utah, United States
  • Frank W. Moler

    2   Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States
  • Kent Page

    1   Department of Pediatrics, University of Utah, Salt Lake City, Utah, United States
  • Victoria L. Pemberton

    3   National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
  • Richard Holubkov

    1   Department of Pediatrics, University of Utah, Salt Lake City, Utah, United States
  • Vinay M. Nadkarni

    4   Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
  • J. Michael Dean

    1   Department of Pediatrics, University of Utah, Salt Lake City, Utah, United States
  • Lenora M. Olson

    1   Department of Pediatrics, University of Utah, Salt Lake City, Utah, United States
Further Information

Publication History

02 April 2018

24 June 2018

Publication Date:
12 August 2018 (online)

Preview

Abstract

The Therapeutic Hypothermia After Pediatric Cardiac Arrest Out-of-Hospital (THAPCA-OH) Trial showed therapeutic hypothermia, versus normothermia, did not significantly improve 1-year survival with good neurobehavioral outcome. Our survey of pediatric critical care physicians, designed to assess the use of targeted temperature management (TTM) after publication of the main THAPCA-OH Trial results, found most respondents were aware of trial results, and over 90% agreed THAPCA-OH was well-designed with important clinical outcomes. While most respondents reported TTM usage consistent with THAPCA-OH results in different patient scenarios, 15% did not select TTM for fever management. Since trials prior to THAPCA-OH established that fever is harmful following brain injury, the continued incomplete adoption of TTM warrants further research on challenges and facilitators to the adoption of clinical trial findings.

Supplementary Material